Which has preferable valuation and earnings, IMRX or REPL?

Immuneering is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.04 N/A Replimune Group N/A N/A -$313.94M -$3.15 N/A

Is IMRX or REPL more profitable?

Immuneering's return on equity of -27.15% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% Replimune Group N/A -159.32% -90.84%

Does the media refer more to IMRX or REPL?

In the previous week, Replimune Group had 20 more articles in the media than Immuneering. MarketBeat recorded 22 mentions for Replimune Group and 2 mentions for Immuneering. Immuneering's average media sentiment score of 0.67 beat Replimune Group's score of 0.18 indicating that Immuneering is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IMRX or GLUE?

In the previous week, Immuneering had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 2 mentions for Immuneering and 1 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.79 beat Immuneering's score of 0.67 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is MGTX or IMRX more profitable?

MeiraGTx has a net margin of 19.87% compared to Immuneering's net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets MeiraGTx 19.87% 283.85% 29.39% Immuneering N/A -27.15% -25.75%

Does the media favor MGTX or IMRX?

In the previous week, MeiraGTx had 4 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for MeiraGTx and 2 mentions for Immuneering. MeiraGTx's average media sentiment score of 0.74 beat Immuneering's score of 0.67 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, OMER or IMRX?

Immuneering is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros N/A N/A -$3.35M $1.28 15.05 Immuneering N/A N/A -$56.03M -$1.04 N/A

Is OMER or IMRX more profitable?

Immuneering's return on equity of -27.15% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Immuneering N/A -27.15% -25.75%

Does the media prefer OMER or IMRX?

In the previous week, Omeros had 9 more articles in the media than Immuneering. MarketBeat recorded 11 mentions for Omeros and 2 mentions for Immuneering. Immuneering's average media sentiment score of 0.67 beat Omeros' score of 0.41 indicating that Immuneering is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immuneering 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, IMRX or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.04 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A

Is IMRX or CRVS more profitable?

Immuneering's return on equity of -27.15% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media prefer IMRX or CRVS?

In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Immuneering. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 2 mentions for Immuneering. Corvus Pharmaceuticals' average media sentiment score of 1.20 beat Immuneering's score of 0.67 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immuneering (IMRX) Competitors

$5.30 +0.05 (+0.95%)

As of 08/21/2026 04:00 PM Eastern

Compare

IMRX vs. REPL, GLUE, MGTX, OMER, and CRVS

Should you buy Immuneering stock or one of its competitors? Immuneering's main competitors and comparable companies include Replimune Group (REPL), Monte Rosa Therapeutics (GLUE), MeiraGTx (MGTX), Omeros (OMER), and Corvus Pharmaceuticals (CRVS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immuneering compare to Replimune Group?

Immuneering (NASDAQ:IMRX) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Immuneering's return on equity of -27.15% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Replimune Group	N/A	-159.32%	-90.84%

67.7% of Immuneering shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 14.9% of Immuneering shares are held by insiders. Comparatively, 5.4% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immuneering currently has a consensus target price of $17.50, suggesting a potential upside of 230.19%. Replimune Group has a consensus target price of $11.86, suggesting a potential downside of 19.72%. Given Immuneering's stronger consensus rating and higher probable upside, equities research analysts clearly believe Immuneering is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Immuneering is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

In the previous week, Replimune Group had 20 more articles in the media than Immuneering. MarketBeat recorded 22 mentions for Replimune Group and 2 mentions for Immuneering. Immuneering's average media sentiment score of 0.67 beat Replimune Group's score of 0.18 indicating that Immuneering is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	3 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuneering has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Summary

Immuneering beats Replimune Group on 9 of the 14 factors compared between the two stocks.

How does Immuneering compare to Monte Rosa Therapeutics?

Immuneering (NASDAQ:IMRX) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Immuneering had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 2 mentions for Immuneering and 1 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.79 beat Immuneering's score of 0.67 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Immuneering has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

Immuneering has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Immuneering's return on equity of -27.15% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

Immuneering currently has a consensus price target of $17.50, indicating a potential upside of 230.19%. Monte Rosa Therapeutics has a consensus price target of $28.50, indicating a potential upside of 99.30%. Given Immuneering's stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

67.7% of Immuneering shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 14.9% of Immuneering shares are held by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Monte Rosa Therapeutics has higher revenue and earnings than Immuneering. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Monte Rosa Therapeutics	$123.67M	9.86	-$38.63M	-$1.76	N/A

Summary

Immuneering beats Monte Rosa Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Immuneering compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Immuneering has lower revenue, but higher earnings than MeiraGTx. Immuneering is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	16.92	-$114.20M	$0.71	20.20
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A

MeiraGTx presently has a consensus target price of $26.17, suggesting a potential upside of 82.47%. Immuneering has a consensus target price of $17.50, suggesting a potential upside of 230.19%. Given Immuneering's higher possible upside, analysts clearly believe Immuneering is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, MeiraGTx had 4 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for MeiraGTx and 2 mentions for Immuneering. MeiraGTx's average media sentiment score of 0.74 beat Immuneering's score of 0.67 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 14.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MeiraGTx has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

MeiraGTx has a net margin of 19.87% compared to Immuneering's net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Immuneering	N/A	-27.15%	-25.75%

Summary

MeiraGTx beats Immuneering on 10 of the 14 factors compared between the two stocks.

How does Immuneering compare to Omeros?

Omeros (NASDAQ:OMER) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Omeros currently has a consensus price target of $38.00, suggesting a potential upside of 97.20%. Immuneering has a consensus price target of $17.50, suggesting a potential upside of 230.19%. Given Immuneering's stronger consensus rating and higher probable upside, analysts clearly believe Immuneering is more favorable than Omeros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Immuneering is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	15.05
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A

Immuneering's return on equity of -27.15% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Immuneering	N/A	-27.15%	-25.75%

48.8% of Omeros shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 10.5% of Omeros shares are owned by insiders. Comparatively, 14.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Omeros had 9 more articles in the media than Immuneering. MarketBeat recorded 11 mentions for Omeros and 2 mentions for Immuneering. Immuneering's average media sentiment score of 0.67 beat Omeros' score of 0.41 indicating that Immuneering is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immuneering	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Summary

Immuneering beats Omeros on 8 of the 14 factors compared between the two stocks.

How does Immuneering compare to Corvus Pharmaceuticals?

Immuneering (NASDAQ:IMRX) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Immuneering's return on equity of -27.15% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Immuneering has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

67.7% of Immuneering shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 14.9% of Immuneering shares are held by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Immuneering. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 2 mentions for Immuneering. Corvus Pharmaceuticals' average media sentiment score of 1.20 beat Immuneering's score of 0.67 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Immuneering currently has a consensus target price of $17.50, suggesting a potential upside of 230.19%. Corvus Pharmaceuticals has a consensus target price of $33.33, suggesting a potential upside of 130.52%. Given Immuneering's stronger consensus rating and higher probable upside, equities research analysts plainly believe Immuneering is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Immuneering and Corvus Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Immuneering News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRX vs. The Competition

Export

Metric	Immuneering	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$342.90M	$4.01B	$7.37B	$12.83B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-5.10	11.62	272.33	24.21
Price / Sales	N/A	1,342.82	625.09	94.86
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	1.57	17.38	11.25	6.42
Net Income	-$56.03M	-$22.72M	$3.47B	$348.89M
7 Day Performance	4.74%	3.29%	2.09%	0.08%
1 Month Performance	20.73%	8.23%	6.64%	3.88%
1 Year Performance	8.38%	55.05%	25.02%	16.98%

Immuneering Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRX Immuneering	2.9288 of 5 stars	$5.30 +1.0%	$17.50 +230.2%	+8.4%	$342.90M	N/A	N/A	60	News Coverage
REPL Replimune Group	1.7557 of 5 stars	$15.47 +5.7%	$11.86 -23.3%	+160.5%	$1.30B	N/A	N/A	210	Earnings Report Insider Trade
GLUE Monte Rosa Therapeutics	3.1529 of 5 stars	$15.13 -1.7%	$28.50 +88.4%	+196.7%	$1.29B	$123.67M	N/A	90	Positive News
MGTX MeiraGTx	4.1787 of 5 stars	$13.81 +0.3%	$26.17 +89.5%	+83.1%	$1.27B	$397.50M	19.37	300	Insider Trade
OMER Omeros	3.6262 of 5 stars	$17.23 -0.7%	$38.00 +120.5%	+338.0%	$1.25B	$38.42M	13.45	210	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuneering (IMRX) Competitors

IMRX vs. REPL, GLUE, MGTX, OMER, and CRVS

How does Immuneering compare to Replimune Group?

Summary

How does Immuneering compare to Monte Rosa Therapeutics?

Summary

How does Immuneering compare to MeiraGTx?

Summary

How does Immuneering compare to Omeros?

Summary

How does Immuneering compare to Corvus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuneering (IMRX) Competitors

IMRX vs. REPL, GLUE, MGTX, OMER, and CRVS

How does Immuneering compare to Replimune Group?

Is IMRX or REPL more profitable?

Do insiders & institutionals hold more shares of IMRX or REPL?

Do analysts rate IMRX or REPL?

Which has preferable valuation and earnings, IMRX or REPL?

Does the media refer more to IMRX or REPL?

Which has more risk & volatility, IMRX or REPL?

Summary

How does Immuneering compare to Monte Rosa Therapeutics?

Does the media prefer IMRX or GLUE?

Which has more risk & volatility, IMRX or GLUE?

Is IMRX or GLUE more profitable?

Do analysts prefer IMRX or GLUE?

Do insiders and institutionals believe in IMRX or GLUE?

Which has higher valuation & earnings, IMRX or GLUE?

Summary

How does Immuneering compare to MeiraGTx?

Which has better earnings and valuation, MGTX or IMRX?

Do analysts prefer MGTX or IMRX?

Does the media favor MGTX or IMRX?

Do insiders and institutionals hold more shares of MGTX or IMRX?

Which has more risk & volatility, MGTX or IMRX?

Is MGTX or IMRX more profitable?

Summary

How does Immuneering compare to Omeros?

Do analysts recommend OMER or IMRX?

Which has better earnings & valuation, OMER or IMRX?

Is OMER or IMRX more profitable?

Do insiders & institutionals hold more shares of OMER or IMRX?

Does the media prefer OMER or IMRX?

Which has more volatility and risk, OMER or IMRX?

Summary

How does Immuneering compare to Corvus Pharmaceuticals?

Is IMRX or CRVS more profitable?

Which has more volatility and risk, IMRX or CRVS?

Do institutionals and insiders have more ownership in IMRX or CRVS?

Does the media prefer IMRX or CRVS?

Which has better valuation and earnings, IMRX or CRVS?

Do analysts rate IMRX or CRVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools